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Linkage analysis and DNA sequencing in a family exhibiting an X-linked mental retardation (XLMR) syndrome, characterized by
microcephaly, epilepsy, ataxia, and absent speech and resembling Angelman syndrome, identiﬁed a deletion in the SLC9A6 gene encod-
ing the Naþ/Hþ exchanger NHE6. Subsequently, other mutations were found in a male with mental retardation (MR) who had been
investigated for Angelman syndrome and in two XLMR families with epilepsy and ataxia, including the family designated as having
Christianson syndrome. Therefore, mutations in SLC9A6 cause X-linked mental retardation. Additionally, males with ﬁndings sugges-
tive of unexplained Angelman syndrome should be considered as potential candidates for SLC9A6 mutations.In 2001, 33 X-linkedmental retardation (XLMR) genes had
been cloned, of which 26 related to syndromal conditions
(syndromal X-linked mental retardation [MRXS]).1 Since
then, a steadily increasing number of novel genes have
been identiﬁed, both inMRXS and in nonsyndromal (non-
syndromic X-linked mental retardation [MRX]) forms,
with the most up-to date information available via two
XLMR-related websites (see Web Resources). At present,
82 cloned XLMR genes are known; 38 MRXS, 16 MRX,
and 28 related to neuromuscular conditions.2 In the pres-
ent work, we show that mutations in SLC9A6 give rise to
an X-linked mental retardation syndrome in which the
clinical picture overlaps with that of Angelman syndrome
(OMIM 105830).
Severe developmental delay with absent or minimal use
of words, ataxia, and a happy demeanor with disposition
for frequent smiling or spontaneous laughter are typical
ﬁndings in Angelman syndrome.3 Seizures, usually before
three years of age, are seen in more than 80% of cases,
and an abnormal electroencephalogram (EEG) with char-
acteristic patterns of slow- and high-voltage wave rhythms
are seen in almost all cases.4,5 An open mouth with
frequent drooling, abnormal food-related behavior, and
ﬂexed arms occur commonly. Clinical symptoms are
usually not present at birth; delayed growth in headThe Amcircumference often results in microcephaly by age two
years.
The prevalence of Angelman syndrome has been esti-
mated to vary between 1:15,0006,7 and 1:40,000.8,9 Al-
though the principal genetic mechanisms interfere with
the expression of UBE3A on chromosome 15q11-q13, ap-
proximately 10%–15% of cases with Angelman syndrome
are apparently unrelated to changes in the 15q11-q13
region.10 In some of these cases, other conditions mimick-
ing Angelman syndrome have been diagnosed;11 such as
Rett syndrome, for example.12 On the basis of the ﬁndings
given below, we suggest that mutations of SLC9A6, encod-
ing the Naþ/Hþ exchanger protein NHE6, should be added
to the list of alternative genetic mechanisms causing an
Angelman syndrome-like phenotype.
We examined three affected males in the same family
(Figure 1A), all of whom exhibited profound developmen-
tal delay, seizures, ataxia, ﬂexed arms, hyperkinetic behav-
ior, and a happy demeanor with frequent smiling and
occasional spontaneous laughter. Initially, they had been
suspected of having Angelman syndrome, but relevant
genetic examinations regarding this diagnosis had been
negative. Normal methylation and negative linkage to the
critical 15q11-q13 region, as well as a normal sequence of
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Figure 1. Inheritance of Phenotypes Mimicking Angelman Syndrome Attributed to SLC9A6 Mutations
(A) Pedigree of a Norwegian family linked to Xq24-q27.3. Affected males are indicated by filled squares, carrier females by circles
containing a dot. The pictures show individual III-5 (left), aged two years, and individual III-4 (right), aged eight years, demonstrating
tendency towards flexed arms, open mouth with drooling, and a happy disposition.
(B) Pedigree of the Swedish family. Individual III-1, aged six years, demonstrates a happy disposition and an open mouth with drooling.
(C) Pedigree of the UK family with picture of individual II-5, aged three years, demonstrating an open mouth with drooling and II-1, aged
20 years, with severe kyphoscoliosis.
In (B) and (C), only individuals marked with an asterisk were tested as part of this investigation.15q. Because the pedigree was consistent with X-linked
inheritance, multipoint parametric linkage analysis was
performed with the three affected males and seven unaf-
fected relatives. A panel of 48 polymorphic microsatellite
markers, spanning the X chromosome with an average
distance of 3.9 cM, was genotyped. Linkage analysis was
performed with GENEHUNTER-PLUS13 assuming fully
penetrant X-linked recessive inheritance and a frequency
of 0.0001 of the disease allele. A maximum LOD score of
1.50 was observed in the Xq24-q27.3 interval, and haplo-
type analysis identiﬁed that the closest recombination
breakpoints limited the interval to a 23.31 cM (26.7 Mb)
region containing 141 known genes.
Candidate-gene selection was aided by four freely avail-
able computer programs designed to guide prioritization.141004 The American Journal of Human Genetics 82, 1003–1010, AprA higher priority was assigned to genes identiﬁed by more
than one method. Coding exons and exon-intron bound-
aries were sequenced for the following genes: GRIA3,
GLUD2, UBE2A, SLC9A6, RBMX, FGF13, THOC2, ODZ1,
and ZNF449 with an Applied Biosystems (Foster City,
CA) 3730 DNA Analyzer. A 6 bp deletion within the coding
sequence of the SLC9A6 gene, localized to Xq26.3, was
found to segregate with affected males and carrier females.
This deletion results in the loss of two highly conserved
amino acid residues (p.E255_S256 del) from the Naþ/Hþ
exchanger domain of the encoded NHE6 polypeptide
(see Figure S1, available online), which shows tissue-wide
expression.15 A hydrophobicity plot of the NHE6 polypep-
tide places the deleted residues in a region of only moder-
ate transmembrane potential (data not shown), butil 2008
homology to other experimentally studied homologous
NHE isoforms would suggest that the deletion falls within
a transmembrane domain.16 Importantly, the deleted resi-
dues have been shown to be essential for ion transport in
the related Naþ/Hþ exchangers NHE1 and NHE8.17–19
Examination of X chromosomes from 278 normal individ-
uals (males and females) for the presence of the 6 bp
deletion was negative, indicating that this sequence
variant was not a common polymorphism.
Further Families Included for Study. In addition to the
original Norwegian family, we sequenced DNA for muta-
tions in SLC9A6 in male probands from ﬁve Norwegian,
14 Swedish, one UK, and 50 American families. The
Norwegian, Swedish, and UK cases had an Angelman syn-
drome-like phenotype and had tested negative for 15q
ﬁndings andMECP2mutations. The criterion for inclusion
of the American cases was that they had tested negative for
15q involvement related to Angelman syndrome. An un-
known number had also been tested forMECP2mutations.
A further XLMR family was obtained from the IGOLD
(International Genetics of Learning Disability; see Web Re-
sources) sequencing study, an independent XLMR project.
An SLC9A6 mutation was found in a male patient from
Sweden (Figure 1B). The mutation creates an Opal stop
codon that prematurely truncates the predicted protein
(p.R468X), removing the ﬁnal transmembrane domain
and C terminus. Alternatively, the stop codon could also
initiate a nonsense-mediated mRNA decay.20 A splice-site
mutation causing skipping of exon 3 (p.V144_R169 del)
was identiﬁed in a UK family (Figure 1C) from the IGOLD
sequencing study. This mutation removes the entire pre-
dicted fourth transmembrane domain of the protein,15
and will therefore likely affect the folding of the protein
within the membrane.
Figure 2. Mutations Found in SLC9A6
Sequence traces of wild-type (upper) and
patient (lower) DNA, with corresponding
amino acid single-letter codes. Sequences
shown are from affected male patients
from (A) Norwegian (Figure 1A), (B) Swed-
ish (Figure 1B), (C) South African (Christi-
anson et al, 199921), and (D) UK
(Figure 1C) families. Intronic DNA se-
quences are shown in lower case. Deleted
or altered bases are underlined.
We also examined DNA from two
affected males of a South African
family of Afrikaans-speaking origin
previously described and published
by Christianson et al.21 (Christianson
syndrome, OMIM 300243), and we
identiﬁed a 2 bp deletion. This family
was included because it showed link-
age of an overlapping interval of the
Xq24-Xq27 region and shared several
clinical features with the Norwegian family. The deletion is
predicted to introduce a frameshift, truncating the NHE6
polypeptide at residue 171 (p.H171fs) and introducing 59
residues of nonsense-derived sequence. All the SLC9A6
mutations are detailed in Figure 2. In addition, an align-
ment showing the mutations in the SLC9A6 protein in the
context of orthologous multiple-sequence conservation is
presented in Figure S1. Primer sequences used to amplify
and sequence SLC9A6 exons can be provided on request.
Phenotypic Features. Table 1 summarizes the phenotypic
features and the corresponding mutations in the four
families. In the Norwegian family, the three affected males
in Figure 1A (III-2, born 1998; III-4, born 1996; and III-5,
born 2002) appeared normal at birth. Deceleration of
head growth occurred in the ﬁrst year of life. At the last
examination, their occipitofrontal head circumferences
(OFCs) ranged between 2 and 4 cm below the 2.5th percen-
tile. Epilepsy occurred between nine and 26 months. All
three cases exhibited a happy demeanor with frequent
smiling and episodes of unprovoked laughter, sometimes
lasting for several hours, particularly at night. A video
ﬁlm (of cases III-2 and III-5) displaying ataxia, hyperkinetic
movements, and smiling is provided online as Supplemen-
tal Data. The deep tendon reﬂexes were hyperactive, and
the plantar responses were inverted. Other notable features
included an open mouth, profuse drooling, swallowing
difﬁculties, and frequent regurgitations due to gastro-
esophageal reﬂux. They had a thin body habitus; weight
in relation to height ranged from the 10th percentile to be-
low the 2.5th percentile. Case III-4 was successfully treated
for standard-risk acute lymphatic leukemia between 6 and
81⁄2 years of age. Case III-2 was transiently treated for
systemic hypertension of unknown cause. He has been in-
vestigated for hirsutism and hyponatremia, suggesting anThe American Journal of Human Genetics 82, 1003–1010, April 2008 1005
Table 1. Phenotypic Findings in Four Families with SLC9A6 Mutations
Affected Males: Total
Number (Examined) Family 1 Norway: 3 (3) Family 2 Sweden: 2 (1) Family 3 UK: 3 (3) Family 4 South Africa21: 16 (4)
Development and Behavior
Profound delay þ þ þ þ
Verbal language absent þ þ þ þ
Easily provoked laughter þ þ þ 
Sleep disturbance 1/3 þ 1/3 NR
CNS Findings
Epilepsy þ þ þ þ
Ataxia þ þ þ þ
Hyperkinetic movements 2/3  þ 
Squint þ þ þ þ
Physical Findings
Microcephaly þ 2.5th percentile þ 3/4
Open mouth þ drooling 2/3 þ þ NR
Swallowing difficulty 2/3 þ 1/3 1/4
Flexed arms þ NR 1/3 þ
Electroencephalography
Epileptiform activity þ þ þ þ
Background frequency 10-11 Hz 1.5-3 Hz 4-7 Hz 3-6 Hz to 11-14 Hz
Brain MRI/Autopsy
Cerebellar atrophy 1/3 NR NR 2/4









All DNA mutations relate to cDNA reference sequence NM_006359.
þ indicates ‘‘present in all examined cases’’; ‘‘-‘‘ indicates ‘‘not present’’; MRI denotes ‘‘magnetic resonance imaging’’; NR denotes ‘‘not recorded.’’underlying endocrinological defect such as congenital ad-
renal hyperplasia. Recently, he was found to have a V281L
mutation in CYP21A2, the gene most commonly associ-
ated with 21-hydroxylase deﬁciency (OMIM 201910). At
present, we do not know if he is compound heterozygote
or if only one allele is affected. In the latter case, we could
speculate that the SLC9A6mutation precipitated his endo-
crinological symptoms.
In the Swedish family (Figure 1B), only case III-1 was
available for clinical examination. He was born at term,
with normal weight and height. His general development
was delayed, and he never established proper eye contact
or obtained an expressive verbal language. He learned to
walk independently at 18 months. Epilepsy was diagnosed
at 16 months, with multiple seizure types: generalized
tonic clonic seizures (GTCs), tonic seizures, and attacks
of complex motor seizures with hand and jawmovements,
accompanied by autonomic nervous system symptoms
such as dilatation of the pupils. Other features include
a happy demeanor with frequent smiling and outbursts
of laughter (day and night), an open mouth and frequent
drooling, and mild kyphosis. Although he can move rela-
tively quickly on a ﬂat surface, his gait is unsteady because
of ataxia. Deep tendon reﬂexes were normal, and there was
no spasticity.1006 The American Journal of Human Genetics 82, 1003–1010, ApIn the UK family, all three half siblings had similar facial
features, with a long face, pointed jaw with profuse drib-
bling, absent speech, poor growth parameters, and variable
ambulatory capacity (Figure 1C). They exhibited a happy
demeanor with frequent smiling. The oldest patient (case
II-1), age 25 years old, had developed a severe kyphoscolio-
sis. He was thin, with little subcutaneous fat. Muscle
strength and tendon reﬂexes were regarded as normal.
Of the 16 affected males in the pedigree published by
Christianson et al.,21 a clinical appraisal was presented
for four affected males aged 10, 20, 24, and 37 years. Their
features included profound mental retardation, micro-
cephaly (n ¼ 3), epilepsy, ataxia, absence of expressive
verbal language, impaired eye movements (ophthalmople-
gia), and squint. They had some craniofacial dysmorphism
(long narrow face, long nose, and prognathic jaw) and
decreased muscle bulk. A slow regression had been noted;
for example, the ability to walk had been lost with advanc-
ing age. The youngest, the only patient who was ambula-
tory, displayed a friendly demeanor.
EEG and Neuroradiological Examinations. EEG examina-
tions were performed in all affected individuals in the Nor-
wegian family (Table 1). Apart from frequent epileptiform
activity, the EEG recordings showed repeated runs of ap-
proximately 10 Hz activity (data not shown) before tworil 2008
Figure 3. Neuroradiological Examinations
(A and B) Magnetic Resonance Imaging (MRI). Saggital T1-weighted MRI examination of the brain in Norwegian patient III-2 (see
Figure 1A) at age four years (0.5 Tesla) (A) and seven years (1.5 Tesla) (B), showing progressive cerebellar atrophy.
(C and D) MR spectra (TE ¼ 30 ms), also from Norwegian patient III-2 at seven years of age. Spectral peaks for inositol (Ins), choline
(Cho), creatine (Cr), and N-acetylaspartate (NAA) are indicated. Increased amounts of the glutamate-glutamine complex (arrow) are sug-
gested by the increased glutamate-glutamine:Cr ratio in the basal ganglia (C), whilst normal metabolite levels were seen in deep cerebral
white matter (D). The illustrations to the right in the panels indicate the position of the voxels of interest (dimensions 2 3 2 3 2 cm).years of age, an abnormally fast rhythm considering their
young age.22
For Norwegian patient III-2 (see Figure 1A and Table 1),
a magnetic resonance imaging (MRI) examination was per-
formed at four and seven years of age. The examinations
included sagittal T1-weighted spin-echo, transverse and
coronal T2-weighted, inversion recovery T1-weighted, and
ﬂuid-attenuated inversion recovery images. Progressive
cerebellar atrophy was evident during the period that
elapsed between the examinations (Figures 3A and 3B).
Proton magnetic resonance spectroscopy (MRS) was also
performed at seven years of age in Norwegian patient
III-2. Single-voxel MRS of the brain was performed withThe Ama point-resolved spectroscopy sequence with chemical-
shift water suppression (repetition time [TR] 1500 ms,
echo time [TE] 30 ms). Volumes of interest were located
in the left parietal white matter and in the right basal
ganglia. The interpretation of the MRS study was limited
because consent was only given for examination of a single
patient and we were unable to use absolute metabolite
concentrations. Nonetheless, it suggested increased levels
of glutamate-glutamine complex in the basal ganglia
(Figures 3C and 3D).
Naþ/Hþ Exchange. The Naþ/Hþ exchanger (NHE) protein
family is composed of at least nine members, with mem-
bers NHE1-5 found in the plasmamembrane andmemberserican Journal of Human Genetics 82, 1003–1010, April 2008 1007
NHE6-9 in the membranes of intracellular organelles.23
The NHE proteins consist of an N-terminal domain of
10–12 transmembrane helices mediating ion exchange,
and a regulatory hydrophilic C-terminal domain. There ex-
ist at least two alternatively spliced variants of the SLC9A6
gene,24 although more appear likely according to current
database annotations. NHE6 is found in early recycling
endosomal membranes and transiently associates with
the plasmamembrane.25 In endosomes, NHE6 is suggested
to have a role in regulating lumen pH.19,25 Thus, a possible
consequence of NHE6 inactivity could be lowered endoso-
mal pH and decreased monovalent ion content, both of
which might affect protein folding and trafﬁcking.26
Recycling endosome trafﬁcking is essential for growth of
dendritic spines during long-term potentiation (LTP),27
a process considered to be the molecular basis of learning
and memory.28 Therefore, if mutations in SLC9A6 impair
endosomal trafﬁcking, LTP is likely to be affected. Interest-
ingly, abnormalities in synaptic development and/or
plasticity were shown to be involved in the pathogenesis
of Angelman syndrome.29
Previous studies have shown that the NHE6 protein
colocalizes with internalized transferrin and early endoso-
mal antigen 1 (EEA1) in COS7 cells, suggesting that the
protein is harbored in early endosomes.19 In order to
explore the intracellular function of NHE6, we used
cultured ﬁbroblasts from patient III-2 (Figure 1A) and two
unrelated controls. By using real-time PCR and NHE6-spe-
ciﬁc primers, we veriﬁed that NHE6 was expressed in all
three cell lines at a level similar to that observed in HeLa
cells (data not shown).
We used confocal immunoﬂuorescence microscopy
analysis with endosomal markers to assess endosomal
morphology, size, and distribution. Fibroblast cells grown
on coverslips were permeabilized with 0.05% saponin,
ﬁxed with 3% paraformaldehyde, and stained for ﬂuores-
cence microscopy as described.30 Coverslips were analyzed
with a Zeiss LSM 510 META confocal microscope equipped
with a Plan-Apochromat X63/1.4 and Neo-Fluar X100/
1.45 oil-immersion objectives. Appropriate emission-ﬁlter
settings were included in order to exclude bleed-through
effects. Endosomal morphology, size, and distribution
were assessed with antibodies against the endosomal
markers EEA1, CD63, and lyso-bisphosphatidic acid
(LBPA), and aggregation of ubiquitylated proteins was
assessed with antibodies against ubiquitin (FK2, Afﬁniti).
However, we did not observe any large-scale endosomal
aberrations in ﬁbroblasts from the patient compared with
controls (Figure S2). We therefore evaluated vesicular pH
bymeans of LysoTracker, a dye which ﬂuoresces in an acid-
iﬁed milieu normally found within the lumens of endo-
somes and lysosomes. Fibroblasts from the patient and
the controls were incubated with 250 nM LysoTracker
Red (Molecular Probes) for 5 min. Live cells were analyzed
immediately by ﬂuorescence microscopy to quantify the
amount of LysoTracker-positive structures. Between 20 and
30 cells were quantiﬁed from each sample and scanned at1008 The American Journal of Human Genetics 82, 1003–1010, Aprﬁxed-intensity settings below pixel-value saturation. The
images were processed with the histogram function in
the Zeiss LSM software. However, no differences were visi-
ble between the patient’s and the controls’ cells (Figure S2).
It remains possible that the ﬁbroblasts used in our analysis
might not exhibit aberrations at the endosomal level for
cell-type-speciﬁc reasons, such as functional redundancy
with other NHE family members expressed in ﬁbroblasts
but not in brain cells.
Putative Consequences of SLC9A6 Mutations. Ataxia, spon-
taneous seizures, and growth retardation have been ob-
served in the related Nhe1 null mutant mouse.31 Notably,
mutant Slc9a6 / female and mutant Slc9a6 /0 male
mice show motor hyperactivity and a lowered threshold
for pharmacologically induced seizures (see Deltagen un-
der Web Resources) consistent with the phenotypic abnor-
malities described in our patients. The complete function
of this cation exchanger and how an impaired function
can cause a phenotype similar to Angelman syndrome re-
main to be explored. Both UBE3A and SLC9A6 are involved
in the intracellular protein-processing apparatus: UBE3A in
protein ubiquitylation, and SLC9A6 in regulating endoso-
mal pH and Naþ concentrations. However, how or if they
interact via a common pathway is currently unclear.
Nonetheless, phenotypic features overlapping with
Angelman syndrome were evident to the clinical investiga-
tors of both the Swedish patient (M. Ky.) and the Norwe-
gian patients (P.S.). On the basis of the four families
included in the present study, we propose that the
‘‘SLC9A6-opathies’’ encompass a clinical spectrum of
feature clusters ranging from those typical of Angelman
syndrome to those typical of Christianson syndrome.
However, the most Angelman syndrome-like patients (III-
2, III-4, and III-5 in Figure 1A; II-1 in Figure 1B; and II-5
in Figure 1C) were also the youngest (<10 years), whereas
three of the patients described by Christianson et al.21 were
R 20 years of age. These patients had gradually lost their
ability to walk. The youngest patient, a 10-year-old boy,
was ambulatory with support and was the only one
described to be ‘‘friendly and approachable.’’ This could
indicate that SLC9A6 mutations cause a slow progression
of symptoms and that resemblance to Angelman syn-
drome is more striking at a younger age. Cerebellar atro-
phy, demonstrated on MRI examination in one of our
patients (see Figure 3), was reported on autopsy in another
case described by Christianson et al.21 Developmental
regression and cerebellar atrophy could indicate SLC9A6
mutation rather than 15q-related Angelman syndrome.
However, the clinical picture in Angelman syndrome can
progress as some adult patients lose their ability to walk
and develop spinal deformities.32,33 Interestingly, these
features were prominent in the oldest UK patient (II-1 in
Figure 1C).
Almost all patients with SLC9A6 mutations were
observed to be very thin. This is in contrast to the symp-
tom of Angelman syndrome in which older patients tend
to become obese.33 Another distinguishing feature wasil 2008
the rapid background frequency of 10–14 Hz on EEG ob-
served in some patients (see Table 1). A slow frequency of
1.5–3 Hz with high voltage (300 mV), an EEG pattern ob-
served in Angelman syndrome,34 was observed only in
the Swedish patient.
We speculate that the patients’ phenotype might result,
at least in part, from glutamate-glutamine accumulation
(see Figure 3) as an indirect consequence of SLC9A6-muta-
tion-initiated loss of function. Glutamate is excitotoxic at
high levels and has been associated with a variety of clini-
cal neurological abnormalities, including epilepsy and
cerebellar degeneration.35 Notably, changes in pH have
been shown to affect glutamine transport,36 which, as
discussed above, could be affected by a loss of NHE6 func-
tion. Alternatively, aberrant glutamate-glutamine trans-
porter trafﬁcking could underlie the elevated levels
observed by proton MRS (Figure 3C).
Carrier Females. In the family described by Christianson
et al.,21 there were ten female carriers of whom three
were either mentally retarded or had learning problems.
None of the carriers displayed selective X inactivation. In
the Norwegian family, carrier females II-2 and II-4
(Figure 1A) were available for assessment. They did not
display clinical symptoms. An EEG examination of II-4
was normal. X-inactivation analysis was performed on
DNA from lymphocytes37 of all three carrier females in
the family, and all showed X-inactivation ratios that were
normal for their age. Female carrier II-5 in the Swedish
family (Figure 1B) had severe dyslexia. Clinical symptoms
were not reported in the carrier mother of the UK patients
(Figure 1C). Therefore, the range of carrier phenotypes
possible with SLC9A6mutation could depend on the sever-
ity of the mutation, functional overlap with other solute
carrier proteins, or genetic-modiﬁer effects.
In conclusion, our study showed that mutations in
SLC9A6 lead to a syndrome associated with microcephaly,
seizures, ataxia, and absent speech. Some patients, particu-
larly those who were in a younger age group, displayed
symptoms resembling those of Angelman syndrome. We
suggest that disruption of SLC9A6 should be considered
in male patients with a non-15q11-13-related Angelman
syndrome phenotype, particularly when X-linked inheri-
tance in the family is suspected.
Supplemental Data
Supplemental data include two ﬁgures and two movies and are
available with this paper online at http://www.ajhg.org/.
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